Skip to main content
OpenTrials
Completed

NCT Number: NCT03157050

Intravenous Iron May Increase Depression Among Hemodialysis Patients

the aim of this study is to assess whether increased ferritin after intravenous iron therapy will lead to increased prevalence of major depression among treated patients.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age was above 19 years,
  • patient on maintenance hemodialysis,
  • patient had iron deficiency anemia (ferritin > 100 ng/ml)

Exclusion criteria

  • patient has history of depression or already using antidepressant medication,
  • Lack of ferritin level increase ≥ 50% from baseline level before IV iron administration,
  • patient already on oral or intravenous iron supplement

Treatment and study plan

Intravenous iron therapy

Other

each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses

Primary outcomes

  1. Change in patient health questionnaire-9 score

    Time frame: on day 0 of start of intravenous iron and 1 week after completion of intravenous iron

    change in patient health questionnaire-9 score before and after intravenous iron therapy

Sponsors and collaborators

Lead sponsor

Benha University

Other

Collaborators

  • New Jeddah Clinic Hospital

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 17, 2017
Registry last updated
May 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.